Bill Flores sold Pfizer Inc (NYSE: PFE)
Bill Flores (R-TX), a U.S. Representative, has disclosed 1 trade in Pfizer Inc (PFE) since 2014, a single sale, worth an estimated $75K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Bill Flores sold $50,001 - $100,000 of Pfizer Inc (NYSE: PFE) on July 8, 2014. Since that trade, PFE is up +47.07% against the S&P 500 up +353.46%, an outperformance of -306.39%.
Data updated
Bill Flores's PFE trades vs the price
PFE is up +47.07% since Bill Flores sold on July 8, 2014, versus +353.46% for the S&P 500.
Performance since this trade
All Bill Flores PFE trades
Bill Flores & PFE trading FAQ
Is it legal for Bill Flores to trade Pfizer Inc (PFE) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Pfizer Inc (PFE), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Bill Flores sell PFE?
Bill Flores disclosed a sale of $50,001 - $100,000 of Pfizer Inc (PFE) on July 8, 2014, according to public STOCK Act filings.
How has PFE performed since Bill Flores's trade?
Since Bill Flores sold PFE on July 8, 2014, the stock is up +47.07%, versus +353.46% for the S&P 500 over the same period, an outperformance of -306.39%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional PFE trades?
Quantellect tracks every disclosed congressional trade in Pfizer Inc (PFE) on the Pfizer Inc congressional trading page, which aggregates filings across all members of Congress.
Bill Flores's PFE tradesAll congressional filings for Pfizer IncBill Flores's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.